Pacritinib (Vonjo) is a kinase inhibitor indicated for the treatment of intermediate- or high-risk primary or secondary myelofibrosis in patients with a platelet count below 50×10⁹/L. Due to its specific safety requirements and risk management regulations, strict rules must be followed for its purchase and use.
How to Purchase Pacritinib (Vonjo)
1. Overseas Purchase
(1) Patients may choose to consult and purchase Pacritinib at hospital pharmacies or licensed retail pharmacies in countries or regions where the drug has been approved for marketing.
(2) Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.
2. Purchase through Medical Service Institutions
(1) Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.
(2) These institutions usually provide legal import channels and can offer professional consultation and guidance.
Precautions for Purchasing Pacritinib (Vonjo)
1. Essential Examinations Before Medication Use
(1) Laboratory Tests: Include complete blood count, coagulation function, electrocardiogram (ECG), and electrolyte levels.
(2) Contraindication Screening: Exclude patients with active bleeding, severe infection, QTc interval > 480 milliseconds, or hepatic impairment (Child-Pugh Class C).
2. Restrictions for High-Risk Populations
(1) Bleeding Risk: Contraindicated in patients with active bleeding. Patients scheduled for surgery should discontinue the drug 7 days in advance.
(2) Cardiovascular Risk: Patients with a smoking history or cardiovascular disease require careful assessment before use.
(3) Pregnancy and Lactation: Contraindicated during pregnancy. Lactating women should avoid breastfeeding within 2 weeks after discontinuing the drug.
3. Long-Term Monitoring Requirements
(1) Monthly Monitoring: Platelet count and renal function.
(2) Quarterly Monitoring: Thyroid function and electrocardiogram (ECG).
(3) Annual Monitoring: Skin cancer screening (especially for smokers).
How to Identify Authenticity of Pacritinib (Vonjo)
1. Packaging Features
(1) Specification Marking: Each capsule contains 100mg of the active ingredient. It is an opaque, oval-shaped capsule with a red cap printed with "Pacritinib 100mg" and a gray body printed with "C78837".
(2) Manufacturing Information: The outer packaging should clearly display the manufacturer information "Sobi, Inc." and the FDA approval number.
2. Channel Verification
(1) Official Channels: Verify the batch number through the contact information provided on the drug packaging or the official website.
(2) Beware of Illegal Sources: Unauthorized online pharmacies and personal purchasing agents are high-risk channels, which may involve counterfeit drugs.
